<DOC>
	<DOCNO>NCT00318500</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety two dos ERB-041 ( 75 mg 150 mg ) relative placebo relief endometriosis-related symptom ( dysmenorrhea , pelvic pain , deep dyspareunia ) reproductive age woman .</brief_summary>
	<brief_title>Study Evaluating Safety Efficacy ERB-041 Reduction Symptoms Associated With Endometriosis Reproductive-Aged Women</brief_title>
	<detailed_description />
	<mesh_term>Endometriosis</mesh_term>
	<mesh_term>Pelvic Pain</mesh_term>
	<mesh_term>Dysmenorrhea</mesh_term>
	<mesh_term>Dyspareunia</mesh_term>
	<criteria>Surgical diagnosis endometriosis within last 10 year Sexually active , nonpregnant , nonlactating woman ( 1845 year ) regular menstrual cycle willing use nonhormonal contraception Conditions require use chronic pain therapy Prophylactic use analgesic avoid endometriosisrelated pain</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Endometriosis</keyword>
	<keyword>Dysmenorrhea</keyword>
	<keyword>Pelvic pain</keyword>
	<keyword>Dyspareunia</keyword>
</DOC>